Clinical Trial: A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07743671) titled 'A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)' on July 29.

Brief Summary: The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Hereditary Hemorrhagic Telangiectasia

Intervention: DRUG: Engasertib

Engasertib will be administered as oral capsules.

DRUG: Placebo

Placebo will be ...